MAPT and Alzheimer disease: Zhang et al. used recombinant adeno-associated virus rAAV as a carrier to introduce the single-chain antibody scFV targeting abnormal phosphorylated Tau protein (P-Tau) into the brain, successfully inducing the continuous expression of scFV in vivo for AD immunotherapy [88].